Subcutaneous anifrolumab improves BICLA response by 15.5% in moderate to severe SLE
Anifrolumab injection improves lupus outcomes in trial
This phase 3 RCT in 367 adults with moderate to severe SLE found that subcutaneous anifrolumab 120 mg weekly plus standard therapy improved …
A weekly injection of anifrolumab helped more people with lupus achieve disease control than placebo, a phase 3 trial shows.
SLE-DAS Responder Index shows 34% response rate in systemic lupus erythematosus trials
New Lupus Measurement Tool Predicts Patient Quality of Life Improvements
This post-hoc analysis of three randomized trials in 438 patients with systemic lupus erythematosus found that 34.0% achieved SLE-DAS Respon…
• A new lupus activity score tracks real patient improvements better • Helps people in clinical trials get effective treatments faster • Sti…
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
Belimumab and anifrolumab show different strengths for lupus patients
This meta-analysis compared belimumab and anifrolumab using indirect evidence from randomized controlled trials involving 4332 patients with…
A new analysis compares two lupus drugs. Belimumab worked better for overall disease control, while anifrolumab helped lower steroid doses a…
Anifrolumab shows higher remission rates versus placebo in SLE patients regardless of immunosuppressant history
A New Lupus Drug May Work Better If You Start It Sooner
A post hoc analysis of pooled Phase 3 RCT data in 726 patients with moderate-to-severe SLE found higher DORIS remission rates with anifrolum…
Starting a new lupus drug before trying older medications may help patients reach remission faster and with fewer side effects.
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
Could a New Treatment Offer Hope for Patients with Lupus?
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
A new subcutaneous treatment is being tested to help adults with moderate to severe lupus who aren't responding well to standard care.